Skip to content

Register Study Standard Proton Beam Therapy WPE - Children -

Register Study Standard Proton Beam Therapy WPE - Children - - KiProReg

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00005363
Enrollment
Unknown
Registered
2013-10-14
Start date
2013-09-16
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Proton beam therapy for childhood malignancies.

Interventions

Group 1: Register Study. Data collection from children receiving proton beam therapy.

Sponsors

Westdeutsches Protonentherapiezentrum gGmbH
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 17 Years

Inclusion criteria

Inclusion criteria: • Indication for radiotherapy was given. • Proton beam therapy is conducted alternatively to conventional radiotherapy. An accountable indication according to § 80 StrlSchV has to be proposed for each patient by a specialized physician including authoritative documentation during proton beam therapy within the scope of patient treatment. The designated use of proton beam therapy is in the realm of medical treatment, - as far as it is clinically established (e.g. according to guidelines) or - as far as the indication and treatment scheme (fractionation, total dosis) is equivalent to the established standard of conventional photon therapy. • Patient does not participate in clinical studies concerning proton beam therapy. • No pregnancy verified. If necessary, willingness to use contraception during treatment is given. • The parents and the patient have given informed consent for participation, data documentation, and analysis in the Register Study.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

MeasureTime frame
The primary end point is the data collection due to the character of a register study. Data will be collected on toxicity, tumor control, and outcome during proton beam therapy as basis for later evaluation concerning options and benefits of protonbeam therapy.

Secondary

MeasureTime frame
(see above)

Countries

Germany

Contacts

Public ContactStefanie Schulze Schleithoff

Westdeutsches Protonentherapiezentrum Essen

stefanie.schulze-schleithoff@uk-essen.de0201/723 6607

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 7, 2026